These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1771812)

  • 1. [Relation of HLA antigens to prognosis in Hodgkin's disease].
    Prazák J; Chytrý P; Hermanská Z
    Vnitr Lek; 1991; 37(9-10):781-8. PubMed ID: 1771812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of HLA antigens in patients with Hodgkin's disease.
    Prazák J; Hermanská Z
    Eur J Haematol; 1989 Jul; 43(1):50-3. PubMed ID: 2788584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA and MLC typing in patients with Hodgkin's disease.
    Hansen JA; Young CW; Whitsett C; Case DC; Jersild C; Good RA; Dupont B
    Prog Clin Biol Res; 1977; 16():217-27. PubMed ID: 143667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Does the presence of HLA-B5 and B35 antigen signify a worse prognosis for Hodgkin's disease? Preliminary report].
    Prazák J; Hermanská Z
    Vnitr Lek; 1988 Mar; 34(3):270-6. PubMed ID: 3259347
    [No Abstract]   [Full Text] [Related]  

  • 5. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.
    Diepstra A; van Imhoff GW; Karim-Kos HE; van den Berg A; te Meerman GJ; Niens M; Nolte IM; Bastiaannet E; Schaapveld M; Vellenga E; Poppema S
    J Clin Oncol; 2007 Jul; 25(21):3101-8. PubMed ID: 17536082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HLA system antigens in Hodgkin's disease in children].
    Vuković I; Susaković N; Dujić A; Stojimirović E; Marković V
    Bilt Hematol Transfuz; 1977; 5(3-4):59-65. PubMed ID: 615611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.
    Brice P; Bastion Y; Divine M; Nedellec G; Ferrant A; Gabarre J; Reman O; Lepage E; Fermé C
    Cancer; 1996 Sep; 78(6):1293-9. PubMed ID: 8826953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The significance of mediastinal involvement and other risk factors for survival in patients with Hodgkin's disease].
    Melínova L; Hermanská Z; Halíková J; Dienstbier Z; Vacková B; Zámecník J; Skala E
    Vnitr Lek; 1995 May; 41(5):307-12. PubMed ID: 7653060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
    Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
    Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
    Nachbaur D; Greinix HT; Koller E; Krieger O; Linkesch W; Kasparu H; Pober M; Hinterberger W; Hausmaninger H; Heistinger M; Ulsperger E; Karlhuber S; Schwinger W; Lindner B
    Ann Hematol; 2005 Jul; 84(7):462-73. PubMed ID: 15726362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable prognosis after late relapse of Hodgkin's disease.
    Garcia-Carbonero R; Paz-Ares L; Arcediano A; Lahuerta J; Bartolome A; Cortes-Funes H
    Cancer; 1998 Aug; 83(3):560-5. PubMed ID: 9690550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
    Mjaaland I; Ganser D; Freitag EM; Bohndorf W
    Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
    Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study.
    Fermé C; Bastion Y; Brice P; Lederlin P; Diviné M; Gabarre J; Assouline D; Ferrant A; Berger F; Lepage E
    Cancer; 1997 Sep; 80(6):1124-33. PubMed ID: 9305714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.